Comparative Analysis of TARGET and PI-FAB Scores in mpMRI Surveillance After HIFU Therapy for Localized Prostate Cancer - Beyond the Abstract
Multiparametric MRI (mpMRI) is an integral component of the workup for men suspected of prostate cancer by providing a non-invasive cancer assessment. However, in the post-treatment setting, challenges persist in distinguishing between treatment associated changes and signs of residual or recurrent disease. In addition, traditional approaches — such as PSA level monitoring — offer limited utility because the amount of residual viable prostate tissue after ablation may vary significantly.
The study underlines that both TARGET and PI-FAB scores showed good inter-reader agreement and comparable diagnostic performance for monitoring in-field recurrences after HIFU therapy for localized prostate cancer. Both scores may serve as valuable tools for excluding in-field prostate cancer recurrence on follow-up mpMRI. Yet, our findings indicate that the detection of local tumor recurrence after HIFU therapy remains challenging. These limitations underscore the need for further validation and refinement of the scoring systems to optimize MRI surveillance after focal prostate ablation.
From a clinical perspective, enhanced imaging interpretation can have significant implications: More accurate scoring on mpMRI may lead to earlier detection of recurrence and better-informed decisions to adequately tailor follow-up care to each patient’s specific needs. Consequently, improved non-invasive surveillance by mpMRI could reduce unnecessary interventions and help streamline patient management.
In conclusion, this comparative analysis of TARGET and PI-FAB scores in the setting of mpMRI surveillance after HIFU therapy offers a reflective assessment of imaging strategies and scoring methods. Consequently, our study aims to pave the way for enhanced diagnostic performance and improved patient outcomes after focal therapy for localized prostate cancer.
Written by: Antonia M. Pausch, MD, Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland
Reference:
Read the Abstract